CorMedix (CRMD) shares were up over 11% in Thursday trading following its Q2 results and guidance.
Earlier, the company reported a Q2 earnings of $0.29 per diluted share, up from $0.28 a year earlier.
Revenue for the three months ended June 30 was $101.9 million, up from $39.7 million a year earlier.
Analysts polled by FactSet expected $97.4 million.
For 2026, the company kept its revenue guidance of $325 million to $345 million, while raising its adjusted EBITDA guidance to a range of $125 million to $140 million.
Analysts expected $335.3 million for revenue.
Price: 7.95, Change: +0.85, Percent Change: +11.90
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.